1994-1998 北京醫(yī)科大學(xué)（現(xiàn)為北京大學(xué)醫(yī)學(xué)部） 學(xué)士
1998-2003 中國(guó)科學(xué)院上海有機(jī)化學(xué)研究所 博士
2004-2008 美國(guó)明尼蘇達(dá)大學(xué) 博士后
2008-2010 美國(guó)明尼蘇達(dá)大學(xué) 研究助理教授
2010.10-至今 中國(guó)科學(xué)院上海藥物研究所 研究員
現(xiàn)任中國(guó)科學(xué)院上海藥物研究所課題組長(zhǎng)、所級(jí)公共技術(shù)中心核磁技術(shù)服務(wù)部首席技術(shù)專家。
致力于基于核磁共振技術(shù)的蛋白質(zhì)-蛋白質(zhì)、蛋白質(zhì)-小分子相互作用研究，重點(diǎn)圍繞與人類疾病相關(guān)的蛋白質(zhì)質(zhì)量控制相關(guān)調(diào)控蛋白和底物蛋白開(kāi)展工作，探索闡明分子伴侶Hsp90、去泛素化酶USP20、USP25和USP28等的功能調(diào)控分子機(jī)制和結(jié)構(gòu)基礎(chǔ)；發(fā)現(xiàn)靶向Hsp90和USP28、USP25、USP2等的抑制劑和變構(gòu)調(diào)節(jié)劑，并在分子和細(xì)胞水平闡明它們的效應(yīng)機(jī)制；發(fā)現(xiàn)靶向淀粉樣蛋白異常聚集（Aβ、α-synuclein等）的小分子化學(xué)伴侶并解析它們的效應(yīng)機(jī)制等。
上海浦東新區(qū)“明珠工程師”（2023年）
明尼蘇達(dá)大學(xué)Paul D. Boyer & James B. Peter Award（2008年）
美國(guó)癌癥研究學(xué)會(huì)Scholar-In-Training Award（2006年）?
1.?Zhou, C.#, Zhang, J.#, Luo, X.#, Lian, F., Zeng, Y., Zhang, Z., Zhang, H.*, Zhang, N.*, Sodium oligomannate electrostatically binds to Aβ and blocks its aggregation, Journal of Physical Chemistry B, 127(9), 1983-1994, 2023.
2.?Xu, Z.#, Wang, H.#, Meng, Q., Ding, Y., Zhu, M., Zhou, H., Zhang, N.*, Shi, L.*, Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines, Biochemical Pharmacology, 215, 115746, 2023.
3.?Tang, J., Hu, H., Zhou, C.*, Zhang, N.*, Human Aha1's N-terminal extension confers it holdase activity in vitro, Protein Science, 32(9), e4735, 2023.
4.?Gao, J.#, Zhou, C.#, Zhong, Y.#, Shi, L., Luo, X., Su, H., Li, M., Xu, Y., Zhang, N.*, Zhou, H.*, Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines, Biochemical Pharmacology, 207, 115376, 2023.
5.?Zhu, M., Wang, H., Ding, Y., Yang, Y., Xu, Z., Shi, L.*, Zhang, N.*, Ribonucleotide reductase holoenzyme inhibitor COH29 interacts with deubiquitinase ubiquitin-specific protease 2 and downregulates its substrate protein cyclin D1, FASEB Journal, 36(5), e22329, 2022.
6.?Wang, H., Meng, Q., Ding, Y., Xiong, M., Zhu, M., Yang, Y., Su, H., Gu, L., Xu, Y., Shi, L.*, Zhou, H.*, Zhang, N.*, USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines, FEBS Journal, 288(4), 1325-1342, 2021.
7.?Zhou, C.#, Zhang, C.#, Zhu, H.#, Liu, Z., Su, H., Zhang, X., Chen, T., Zhong, Y., Hu, H., Xiong, M., Zhou, H., Xu, Y.*, Zhang, A.*, Zhang, N.*, Allosteric Regulation of Hsp90α's Activity by Small Molecules Targeting the Middle Domain of the Chaperone, iScience, 23(2), 100857, 2020.
8.?Yang, Y., Ding, Y., Zhou, C., Wen, Y., Zhang, N.*, Structural and Functional Studies of USP20 ZnF-UBP Domain by NMR, Protein Science, 28(9), 1606-1619, 2019.
9.?Yang, Y.#, Shi, L.#, Ding, Y., Shi, Y., Hu, H., Wen, Y.*, Zhang, N.*, Structural and Functional Investigations of the N-Terminal Ubiquitin Binding Region of Usp25, Biophysical Journal, 112(10), 2099-2108, 2017.
10.?Yu, J.#, Chen, T.#, Zhou, C.#, Lian, F., Tang, X., Wen, Y., Shen, J., Xu, Y., Xiong, B.*, Zhang, N.*, NMR-based Platform for Fragment-Based Lead Discovery Used in Screening BRD4-targeted Compounds, Acta Pharmacologica Sinica, 37(7), 984-93, 2016.
11.?Wen, Y.#, Shi, L.#, Ding, Y., Cui, R., He, W.T., Hu, H.*, Zhang, N.*, The N-terminal ubiquitin-binding region of ubiquitin-specific protease 28 modulates its deubiquitination function: NMR structural and mechanistic insights, Biochemical Journal, 471(2), 155-65, 2015.
12.?Zhang, N.#, Wang, Q.#, Ehlinger, A.#, Randles, L.#, Lary, J.W., Kang, Y., Haririnia, A., Storaska, A.J., Cole, J.L., Fushman, D., Walters, K.J.*, Structure of the S5a:K48-linked diubiquitin complex and its interactions with Rpn13, Molecular Cell, 35(3), 280-290, 2009.
13.?Husnjak, K.#, Elsasser, S.#, Zhang, N.#, Chen, X., Randles, L., Shi, Y., Hofmann, K., Walters, K.J.*, Finley, D.*, Dikic, I.*, Proteasome subunit Rpn13 is a novel ubiquitin receptor, Nature, 453(7194), 481-488, 2008.
